benefits of glp-1 agonists Glucagon-like peptide 1 receptor agonists: cardiovascular and mechanisms action Therapeutic benefits of glucagon-like peptide-1

[DOI] [PMC free article] [PubMed] [Google Scholar] 134.Dai Y., Mercanti F., Dai D., Wang X., Ding Z., Pothineni N.V

muciniphila restored mucus layer thickness, reduced gut permeability and endotoxemia, lowered inflammation, and improved insulin sensitivity and metabolic outcomes in high-fatdiet mice

Kidney Int 83:517523 Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

and advisory boards for Altimmune,Inc., Arrowhead Pharmaceuticals, Inc., BioAge, Biolinq Incorporated,Caribou Biosciences, Inc., CinFina Pharma, Inc., Covidien LP, Cowenand Company, LLC, Currax Pharmaceuticals, LLC, EPG CommunicationHoldings Ltd., Form Health, Inc., Fractyl Health, Inc., Lilly USA, LLC, LNutra, Inc., Mediflix Inc., NeuroBo Pharmaceuticals, Inc., NeurocrineBiosciences, Inc., NodThera Limited, Nutrisystem, OptumRx, Inc., PainScript Corporation, Palatin Technologies, Inc., Pursuit By You, RedesignHealth Inc., ReShape Lifesciences Inc., Riverview School, Roman HealthVentures Inc., Scholar Rock, Inc., Terns, Inc., Verily Life Sciences LLC,Veru Inc., Vida Health, Inc., Wave Life Sciences, Xeno Biosciences andZyversa Therapeutics, Inc

Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease: results from the LEADER trial

However, in the covariate analysis of this study, no significant effects of baseline weight, baseline BMI, or proportion of males on the weight-reducing impact of GLP-1RA drugs were found